

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Christopher Thomas BRAIN	06/06/2007
Gebhard THOMA	05/10/2007
Moo Je SUNG	05/14/2007
RECEIVING PARTY DATA	
Name:	Novartis AG
Street Address:	Lichtstrasse 35
City:	Basel
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12302223
CORRESPONDENCE DATA	
Fax Number:	(617)871-3392
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	nibr.maildata@novartis.com
Correspondent Name:	Katherine Kantorski
Address Line 1:	Novartis Institutes for BioMedical Resea
Address Line 2:	220 Massachusetts Avenue
Address Line 4:	Cambridge, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	PAT050225-US-PCT
NAME OF SUBMITTER:	Katherine Kantorski

Total Attachments: 7
 source=Assignment_50225-US-PCT#page1.tif
 source=Assignment_50225-US-PCT#page2.tif

501592279

**PATENT
 REEL: 026579 FRAME: 0815**

CH \$40.00 12302223

source=Assignment_50225-US-PCT#page3.tif
source=Assignment_50225-US-PCT#page4.tif
source=Assignment_50225-US-PCT#page5.tif
source=Assignment_50225-US-PCT#page6.tif
source=Assignment_50225-US-PCT#page7.tif

(joint)

Patent Case 50225

ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we

(1) Christopher Thomas BRAIN, (2) Gebhard THOMA, and (3) Moo Je Sung

respectively residing at

- 1. Novartis Institute for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 USA, citizen of United Kingdom
- 2. Talweg 32, 79540 Lörrach, Germany, citizen of Germany
- 3. 24 Chester Road, Belmont, Massachusetts 02478 USA, citizen of South Korea

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all of our right, title and interest for all countries of the world except Austria and to Novartis Pharma GmbH, a company organized under the laws of Austria, of Brunner Strasse 59, 1230 Vienna, Austria, and its successors, assigns and legal representatives, all of our right, title and interest for Austria (Novartis AG and Novartis Pharma GmbH hereinafter referred to collectively as the "ASSIGNEES") in and to (1) all of our inventions and discoveries described in the patent application(s) titled

PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

and filed in the United States Patent and Trademark Office on 24 May, 20 07 and accorded Application Number PCT/US07/69595 * and/or filed in the RO/_____ on _____, 20____ and accorded International Patent Application Number PCT/_____, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on 26 May 2006 and accorded Application Number 60/808,605 (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of **ASSIGNEES** or their designees or in our names, at their election and in accordance with applicable law in all countries and regions), (6) all continuations and divisions of any United States patent application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said **ASSIGNEES** and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

*We hereby authorize **ASSIGNEES** and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent application(s) when notified thereof.

And we hereby covenant and agree that we will, at any time, (i) upon the request, but at the expense, of **ASSIGNEES** or their successors, assigns or legal representatives execute and deliver all documents that



005

(joint)

Patent Case 50225

ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, we

(1) **Christopher Thomas BRAIN**, (2) **Gebhard THOMA**, and (3) **Moo Je Sung**

respectively residing at

1. **Novartis Institute for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 USA, citizen of United Kingdom**
2. **Talweg 32, 79540 Lörrach, Germany, citizen of Germany**
3. **24 Chester Road, Belmont, Massachusetts 02478 USA, citizen of South Korea**

do hereby sell, assign and transfer to Novartis AG, a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all of our right, title and interest for all countries of the world except Austria and to Novartis Pharma GmbH, a company organized under the laws of Austria, of Brunner Strasse 59, 1230 Vienna, Austria, and its successors, assigns and legal representatives, all of our right, title and interest for Austria (Novartis AG and Novartis Pharma GmbH hereinafter referred to collectively as the "**ASSIGNEES**") in and to (1) all of our inventions and discoveries described in the patent application(s) titled

PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES

and filed in the United States Patent and Trademark Office on 24 May, 2007 and accorded Application Number PCT/US07/69595 * and/or filed in the RO/_____ on _____, 20____ and accorded International Patent Application Number PCT/_____, (2) the patent application(s) identified in (1), (3) all national stages of any international patent application identified in (1), (4) all other patent applications in all countries and regions claiming the priority of the provisional or non-provisional patent application filed in the United States Patent and Trademark Office on 26 May 2006 and accorded Application Number 60/808,605 (5) for all patent applications, all rights of priority based upon the United States patent application identified in (4) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application identified in (4) is a provisional patent application, under 35 USC 119(e) (including the right to file patent applications on said inventions and discoveries in the names of **ASSIGNEES** or their designees or in our names, at their election and in accordance with applicable law in all countries and regions), (6) all continuations and divisions of any United States patent application or international patent application designating the United States identified in (1), any national stages of any international application identified in (1) and any patent applications within the scope of (4) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2)-(4) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said **ASSIGNEES** and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

*We hereby authorize **ASSIGNEES** and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent application(s) when notified thereof.

And we hereby covenant and agree that we will, at any time, (i) upon the request, but at the expense, of **ASSIGNEES** or their successors, assigns or legal representatives execute and deliver all documents that

PATENT
REEL: 026579 FRAME: 0820

Attestation

I, the undersigned notary public of Basel, Switzerland, certify herewith the authenticity of the signature of **Mr. Gebhard Thoma**, German citizen, residing in Lörrach, Germany.

The authenticity of the signature was established by means of comparison.

BASEL, Switzerland, this 16th (sixteenth) day of May 2007 (twothousandandseven)

M. Stecher, Notar

Leg.Prot.Nr. 883 /2007